title: The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis.
abstract: OBJECTIVE
  We evaluated the predictors of recurrent restenosis and the impact of lesion length and vessel size on outcomes in patients treated with routine sirolimus-eluting stent (SES) implantation for in-stent restenosis (ISR) of bare-metal stent (BMS).
  
  
  METHODS
  In this study, 250 consecutive patients with 275 lesions after SES implantation for ISR of BMS were enrolled. Follow-up angiogram was obtained in 239 patients with 258 lesions eight months after implantation (follow-up rate: 95.6%). We compared characteristics of patients and lesions between the two groups (the recurrent restenosis group and the no-restenosis group).
  
  
  RESULTS
  Recurrent restenosis was angiographically documented in 43 lesions (16.7%). Recurrent restenosis was found in 30.4% with small vessel lesions (reference diameter of less than 2.5 mm, 92 lesions) and 23% with the diffuse type lesions (106 lesions). Seventy-two per cent of patients had a focal pattern of recurrent restenosis. Previously recurrent ISR lesions (odds ratio (OR) 1.94, 95% confidence interval (CI) 0.94 to 4.06, p = 0.05), reference diameter of less than 2.5 mm (OR 2.41, CI 1.05 to 5.41, p = 0.03), diffuse type restenosis (OR 4.48, CI 2.12 to 9.94, p = 0.0001) and dialysis patients (OR 4.72, CI 1.42 to 15.7, p = 0.01) were independent predictors of recurrent restenosis.
  
  
  CONCLUSIONS
  Small vessels, diffuse type restenosis and dialysis patients were still the predictors of recurrent restenosis in patients treated with SES for ISR of BMS.
authors.affiliation: Department of Cardiology, Kurashiki Central Hospital, 1-1-1 Miwa, kurashiki-shi, Okayama 710-8602, Japan. sh10461@kchnet.or.jp
authors.forename: S
authors.initials: S
authors.lastname: Habara
authors.forename: K
authors.initials: K
authors.lastname: Mitsudo
authors.forename: T
authors.initials: T
authors.lastname: Goto
authors.forename: K
authors.initials: K
authors.lastname: Kadota
authors.forename: S
authors.initials: S
authors.lastname: Fujii
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
authors.forename: H
authors.initials: H
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Takenaka
authors.forename: Y
authors.initials: Y
authors.lastname: Fuku
authors.forename: S
authors.initials: S
authors.lastname: Hosogi
authors.forename: A
authors.initials: A
authors.lastname: Hirono
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: D
authors.initials: D
authors.lastname: Hasegawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Tasaka
authors.forename: S
authors.initials: S
authors.lastname: Otsuru
authors.forename: Y
authors.initials: Y
authors.lastname: Okamoto
authors.forename: C
authors.initials: C
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Miyamoto
authors.forename: K
authors.initials: K
authors.lastname: Inoue
mesh_terms: D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus